On this pageJump to a section
Wegovy at $1,350 a month. That was the monthly price the White House put on it, and it was the number a lot of cash-pay offers were measured against.
On November 6, 2025, the White House said agreements with the manufacturers would bring Ozempic and Wegovy down from about $1,000 and $1,350 a month to $350 through TrumpRx, and that an oral starting dose would be $150 a month if approved.1 The oral pill was approved about six weeks later. If your offer was "the same thing, cheaper," the ground moved.
Educational content, not legal or medical advice. Talk to your healthcare attorney and your clinical team about your own program.
What changed in GLP-1 economics for telehealth clinics?
Two things landed close together. First, pricing (I covered the deal in GLP-1 Prices Are Falling). The White House fact sheet put branded injectables at $350 a month through its TrumpRx site, and listed Medicare and Medicaid pricing as part of the same agreements.1 Whatever you think of the politics, the effect on a clinic is plain: the drug itself is no longer the thing you are cheaper at.
The oral option
Second, product. On December 22, 2025, Novo Nordisk announced the FDA approval of the Wegovy pill, the first oral GLP-1 for weight loss in adults. The company said the starting dose would be $149 a month with savings offers, available through pharmacies and select telehealth providers.2 That means patients now have a manufacturer-priced option at the pharmacy, not only through you.
~14%
I am not a clinician, and I am not going to interpret trial data for you. I mention the number because it shows the product has real results, which means your marketing does not need to inflate anything.
Why can't you win a branded offer on price?
Because price is now a published fact. When the manufacturer lists a cash price, a patient can look it up in a minute. Your discount is whatever room is left between that number and your costs, and that room is small.
Where margin used to hide
Some weight-loss clinics were built on a spread: a low supply cost against a high price patients would pay for convenience. Branded, manufacturer-priced drugs squeeze that spread. If your entire pitch is a lower number, you are in a race with the company that makes the drug.
What does not change
A drug on a shelf does not manage a person. Someone still has to decide if the patient is eligible, answer questions at 9 p.m. about nausea, keep the refills flowing and notice when a patient disappears. That is a service, and service is where a clinic can build something durable.
What are you actually selling now?
Care. The drug is an ingredient. I would build the offer in layers and price each layer on its own.
| Price offer | Service offer |
|---|---|
| "Cheaper than the pharmacy" | "A clinician who knows your history" |
| A one-time consult and a prescription | A defined onboarding and follow-up schedule |
| Silence until the next refill | Check-ins at set points, with side-effect triage |
| Generic diet advice in a PDF | Nutrition and strength guidance matched to the patient |
| Ghosting when someone stops | A plan for pausing, stopping or switching |
Layer one: the front door
Intake that screens for eligibility honestly and routes patients who should not take the drug to someone else. A clean no is part of the service and protects the brand.
Layer two: the first 90 days
Most of the risk and most of the drop-off lives here. I would define the contact points in advance: a welcome message, a week-one check, a dose-change check and a month-three review. The patient should always know the next date.
Layer three: the long game
Weight management is not a 12-week event. Offer a maintenance plan, refill continuity and a clear path for patients who want to change medication or stop.
Why does retention decide the economics?
Because the drug is only valuable while the patient stays in care (the pattern I described in GLP-1 Patient Retention). Prime Therapeutics, analyzing real-world claims, reported that 71% of people who started a GLP-1 drug for weight loss were no longer taking it after one year, and 85% after two.6 That is one dataset, with its own definitions, but it points at the same thing every operator sees: people drop off.
What happens when they stop
A Cleveland Clinic study of 7,938 adults with obesity or overweight who started injectable semaglutide or tirzepatide and stopped within three to 12 months found that, in the obesity group, 55% gained weight in the year after stopping, while 45% kept losing or stayed the same. Within 12 months, 27% of all patients had switched to a different medication, 20% had restarted the original and 14% continued treatment through lifestyle visits with healthcare professionals.5
I read that as a design brief. The patient who stops is not gone. They are about to make one of several choices, and a clinic with a plan for that moment keeps more of them.
What can you say in your marketing?
Less than you think, and with more precision. On March 3, 2026, the FDA announced 30 warning letters to telehealth companies over false or misleading claims about compounded GLP-1 products on their websites. The letters cited suggesting that compounded products are equivalent to FDA-approved drugs, and marketing under the telehealth firm's own name without making clear that the firm is not the compounder.3
The FDA also reminded the market that compounded drugs skip its approval process, so nobody at the agency checks them for safety, effectiveness or quality before sale.3 Foley & Lardner's summary adds that examples cited in the letters included "generic" terminology and wording that implied FDA approval.4
Former FDA Commissioner Scott Gottlieb, speaking on CNBC in an interview posted on February 9, 2026, said compliance is what decides which telehealth companies drugmakers will work with. He sits on the boards of Pfizer and UnitedHealth, among others, so he is not a neutral observer of this market.7
VideoCNBC Television
Dr. Scott Gottlieb on Novo Nordisk vs. Hims & Hers: We have a drug approval process for a reason
A nine-minute CNBC interview on Novo Nordisk, Hims & Hers and the line between compounding and approval.
Someone who could step into this market and do it in a compliant fashion could partner with drug companies.
I read that as the commercial case for the checklist below. Clean claims are not only protection. They are what a partner will look for first.
A simple way to think about claims
- Say exactly which product the patient is getting and who makes it.
- Never imply that compounded medication matches or equals an approved brand.
- Do not borrow the FDA's name for your own program.
- Have counsel review the pages, the ads and the intake language before you spend on traffic.
Accuracy is a feature you can sell. A clinic that is clear about what it offers looks better next to one that is not.
You cannot out-discount the people who make the drug. You can out-care everyone who treats the prescription as the finish line.
How would I rebuild the offer?
As an ad operator, I look at this as a promise that has to survive contact with the patient. These are the steps I would take.
- List what you deliver beyond the prescription: screening, follow-up, nutrition, strength, refills, and a stop or switch plan.
- Separate the price of the care from the price of the drug, and state both clearly.
- Define the first 90 days as a schedule the patient can see.
- Track persistence at 30, 60, 90 and 180 days, and treat every drop as a lead to follow up.
- Rewrite the ads and pages around the service, and keep every claim reviewed by counsel.
- Test the offer with a small budget before you scale the traffic.
If you are building or fixing a program like this, start on my telehealth page.
Build the part of the offer that a manufacturer's price list cannot copy.
This article is educational and is not legal advice. Talk to a qualified healthcare attorney about your situation.
Keep building.Ekai
Questions people ask
How have branded GLP-1 prices changed?
In November 2025 the White House announced agreements that it said would bring Ozempic and Wegovy from about $1,000 and $1,350 a month to $350 through TrumpRx, with an oral starting dose at $150. Novo Nordisk later priced the Wegovy pill starting dose at $149 a month with savings offers.
Can a telehealth clinic still compete on price?
Not reliably. When the manufacturer sells the drug at a published price, your price advantage shrinks to whatever you can charge for the service around it. The durable edge is intake, follow-up, support and retention.
What did the FDA warn telehealth companies about in March 2026?
On March 3, 2026 the FDA announced 30 warning letters to telehealth companies over false or misleading claims about compounded GLP-1 products. The letters cited suggestions that compounded products are equivalent to FDA-approved drugs and marketing under the telehealth firm's own name without making clear who compounds the drug.
What should a GLP-1 telehealth offer sell besides the drug?
Sell the care around it: eligibility screening, prescriber access, dose and side-effect follow-up, nutrition and strength guidance, refill continuity and a plan for what happens next. This article is educational, not legal or medical advice.
Sources
- 1
- 2
- 3
- 4
- 5
- 6
- 7
